Stock Track | PegBio Soars 18.76% Intraday on Continued GLP-1 Drug Commercialization Momentum

Stock Track

May 22

PegBio Co-B (02565.HK) experienced a significant intraday surge of 18.76%, continuing its recent volatile trading pattern.

The stock's movement is driven by accelerating commercialization efforts for its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio has established a strategic partnership with Tenry Pharma, granting exclusive commercialization rights for Paidakang in mainland China with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million.

Further bolstering commercialization prospects, Tenry Pharma recently signed a cooperation agreement with Ark Health for the online debut of the drug on its internet hospital platform. PegBio's core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets the substantial type 2 diabetes and obesity markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1107511918"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1107511918\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1107511918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 11:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107511918","market":"sg","top_or_hot":-1,"title":"Stock Track | PegBio Soars 18.76% Intraday on Continued GLP-1 Drug Commercialization Momentum","media":"Stock Track","content":"<p>PegBio Co-B (02565.HK) experienced a significant intraday surge of 18.76%, continuing its recent volatile trading pattern.</p><p>The stock's movement is driven by accelerating commercialization efforts for its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio has established a strategic partnership with Tenry Pharma, granting exclusive commercialization rights for Paidakang in mainland China with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million.</p><p>Further bolstering commercialization prospects, Tenry Pharma recently signed a cooperation agreement with Ark Health for the online debut of the drug on its internet hospital platform. PegBio's core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets the substantial type 2 diabetes and obesity markets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PegBio Soars 18.76% Intraday on Continued GLP-1 Drug Commercialization Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PegBio Soars 18.76% Intraday on Continued GLP-1 Drug Commercialization Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-22 11:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PegBio Co-B (02565.HK) experienced a significant intraday surge of 18.76%, continuing its recent volatile trading pattern.</p><p>The stock's movement is driven by accelerating commercialization efforts for its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio has established a strategic partnership with Tenry Pharma, granting exclusive commercialization rights for Paidakang in mainland China with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million.</p><p>Further bolstering commercialization prospects, Tenry Pharma recently signed a cooperation agreement with Ark Health for the online debut of the drug on its internet hospital platform. PegBio's core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets the substantial type 2 diabetes and obesity markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1107511918","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107511918","pubTimestamp":1779420405,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PegBio Co-B (02565.HK) experienced a significant intraday surge of 18.76%, continuing its recent volatile trading pattern.The stock's movement is driven by accelerating commercialization efforts for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"个股追踪|派格生物盘中大涨18.76%GLP-1药物商业化势头持续","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PegBio Co-B (02565.HK) experienced a significant intraday surge of 18.76%, continuing its recent volatile trading pattern.The stock's movement is driven by accelerating commercialization efforts for its GLP-1 drug Paidakang (vipetnapeptide injection). PegBio has established a strategic partnership with Tenry Pharma, granting exclusive commercialization rights for Paidakang in mainland China with a cumulative sales target exceeding RMB 10 billion and upfront royalty payments of approximately HK$140 million.Further bolstering commercialization prospects, Tenry Pharma recently signed a cooperation agreement with Ark Health for the online debut of the drug on its internet hospital platform. PegBio's core product PB-119, a once-weekly long-acting GLP-1 receptor agonist approved in November 2025, targets the substantial type 2 diabetes and obesity markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}